This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health (CVS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 1.17% and 0.17%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What to Expect from CVS Health's Q3 Earnings
by Benjamin Rains
Let's see what to expect from CVS before the opening bell Tuesday.
Should You Buy CVS Stock Ahead of Q3 Earnings?
by Benjamin Rains
Let's see if investors should think about buying CVS stock ahead of its Q3 financial results.
Upcoming Earnings Reports to Watch: CVS, QCOM, DIS
by Ryan McQueeney
Stocks were down in morning trading Friday, putting major indexes on track to snap a three-day winning streak that followed a brutal month of selling. But will next week's earnings results get the rebound back on track? Let's take a closer look at a few of the earnings announcements due during the week of November 5!
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $72.84, moving +0.61% from the previous trading session.
Will CVS Health's (CVS) PBM Strength Boost Q3 Earnings?
by Zacks Equity Research
Despite a challenging pricing scenario, CVS Health (CVS) is currently gaining on high level of service and execution as well as a competitive pricing along with unique integrated model.
Aetna (AET) Q3 Earnings Beat Estimates, Membership Increases
by Zacks Equity Research
Aetna (AET) earnings grow on revenue and membership gains.
CVS Health (CVS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $70.67, moving +1.23% from the previous trading session.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $73.72 in the latest trading session, marking a +0.9% move from the prior day.
Walgreens Boots (WBA) Stock Looks Like A Cheap, Solid Buy Right Now
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) jumped roughly 1.6% Monday as investors continue to dive in after it posted impressive fiscal fourth-quarter results late last week. Looking ahead, the pharmaceutical giant looks poised for strong growth and WBA stock seems like it might be worth buying right now.
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CVS Health (CVS) Stock Moves -0.72%: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $78.92, marking a -0.72% move from the previous day.
Walgreens (WBA) Stock Sinks 1.7% Ahead of Q4 Earnings: What to Watch
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) slipped 1.7% during regular trading hours Wednesday in a sign that investors might be a tad bit nervous about the pharmacy and cosmetic giant's Q4 earnings results Thursday.
The Zacks Analyst Blog Highlights: JPMorgan, American Express, FedEx, PepsiCo and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, American Express, FedEx, PepsiCo and CVS
Top Research Reports for JPMorgan, American Express & FedEx
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), American Express (AXP) and FedEx (FDX).
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FLQL
CVS Health's Aetna Deal Imminent, PBM Selling Season Strong
by Zacks Equity Research
CVS Health (CVS) is steadily approaching the Aetna deal wrap-up. Per the company, this significant buyout might alter the whole Healthcare landscape in the United States.
The Zacks Analyst Blog Highlights: Adobe, United Technologies, Lockheed Martin, CVS Health and Coca-Cola
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Adobe, United Technologies, Lockheed Martin, CVS Health and Coca-Cola
Should You Buy Walgreens Boots (WBA) Stock Ahead of Q4 Earnings?
by Benjamin Rains
Walgreens Boots Alliance (WBA) shares have surged 17% in the last three months to outpace the S&P 500's roughly 7% climb as fears that Amazon's (AMZN) pharmaceutical push would doom the pharmacy giant prove overblown. Now the question is should investors consider buying WBA stock ahead of its Q4 earnings release on October 11?
Top Research Reports for Adobe, United Technologies & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), United Technologies (UTX) and Lockheed Martin (LMT).
Here's Why You Should Invest in CVS Health (CVS) Stock Now
by Zacks Equity Research
CVS Health's (CVS) solid cash position is encouraging. Strong 2019 PBM selling season is another upside.
Is CVS Health (CVS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cigna Gets Merger Nod, Forms Management for Unified Entity
by Zacks Equity Research
Cigna (CI) forms management as it prepares for new merged entity.
WellCare Health's (WCG) Buyout to Expand Medicare Business
by Zacks Equity Research
WellCare Health's (WCG) impending buyout of Aetna's Medicare business to expand and cement its foothold in the rapidly growing market.